Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells.
10.3349/ymj.2011.52.6.990
- Author:
Dae Suk KIM
1
;
Dong Hyun KIM
;
Boncheol GOO
;
Young Hun CHO
;
Jin Mo PARK
;
Tae Hyung LEE
;
Hyun Ok KIM
;
Han Soo KIM
;
Hyunah LEE
;
Jong Doo LEE
;
Dashlkhumbe BYAMBA
;
Jeong Hwan JE
;
Min Geol LEE
Author Information
1. Department of Dermatology and Cutaneous Biology Research Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. mglee@yuhs.ac
- Publication Type:Original Article ; Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Dendritic cell;
immunotherapy;
malignant melanoma
- MeSH:
Dendritic Cells/*cytology;
Enzyme-Linked Immunosorbent Assay;
Flow Cytometry;
Humans;
Immunotherapy/*methods;
Melanoma/*therapy;
Monocytes/*cytology;
Treatment Outcome
- From:Yonsei Medical Journal
2011;52(6):990-998
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. MATERIALS AND METHODS: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4x107 DC were injected each time. RESULTS: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-gamma-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. CONCLUSION: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.
